Market closedADR

I-MAB/$IMAB

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Ticker

$IMAB
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Rockville, United States

Employees

220
Website
ir.i-mabbiopharma.com

I-MAB Metrics

BasicAdvanced
$87M
-
-$1.01
1.08
-

$87M

1.08

$2.08

$0.84

557K

15.989

15.665

1.39

1.735

-1,765.38%

26.365

0.4

0.4

-118.30%

-65.04%

-75.58%

-7.82%

What the Analysts think about I-MAB

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for I-MAB stock.

I-MAB Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

I-MAB Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMAB

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for I-MAB stock?

I-MAB (IMAB) has a market cap of $87M as of January 15, 2025.

What is the P/E ratio for I-MAB stock?

The price to earnings (P/E) ratio for I-MAB (IMAB) stock is 0 as of January 15, 2025.

Does I-MAB stock pay dividends?

No, I-MAB (IMAB) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next I-MAB dividend payment date?

I-MAB (IMAB) stock does not pay dividends to its shareholders.

What is the beta indicator for I-MAB?

I-MAB (IMAB) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.